Skip to main content

Fiscal Wizard · Single-issue tearsheet

CORT / Jun 21, 2026 Run #7498

CORT

Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Composite verdict

B 71.6 / 100
Bullish setup · Trend Following 6 drivers · 2 gates blocking
  • Relative Strength vs SPY
  • Trendline Break
  • Keltner Channels
Consider long call target Δ ~0.60 · ~35 DTE Bullish setup, Grade B → ITM call target

Industry rank 30th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: uptrend
Bull 100%Evidence: High · 18 signals0% Bear
Momentum Bullish 99Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -88%
Asset value $6.03Earnings power value $4.79Price $79.91

Priced above its no-growth earnings power value ($4.79/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

43.3 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Cash Conversion Cycle 100
Margin of Safety 0
Asset Turnover 100
Earnings Yield 0
Days Sales Outstanding 90
EPS Growth (YoY) 0

Technicals Bullish

99.9 / 100

Bullish setup leads (Relative Strength vs SPY, Trendline Break, Keltner Channels); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Relative Strength vs SPY 75
Trendline Break 75
Keltner Channels 72

Risk Gates

2 blocking 6 caution

2 guards active, 21 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

Piotroski F-Score Caution

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for CORT.